Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
We’re delighted that NICE has approved bevacizumab for first- and second-line treatment in combination with chemotherapy for advanced bowel cancer patients in England and Wales, following a similar ...
NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat ...
This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is ...
Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) British National Formulary for Children (BNFC) Life sciences Library and knowledge services What ...
Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) British National Formulary for Children (BNFC) Life sciences Library and knowledge services What ...
Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under. There is a simple discount patient ...
Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments. There is ...
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.
There is a simple discount patient access scheme for efanesoctocog alfa. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic ...
Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) British National Formulary for Children (BNFC) Life sciences Library and knowledge services What ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback